Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 9/20 | 0.46 |
| ▸ | TDO2 | P48775 | 8/20 | 0.46 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8200409 | 0.83 | ALDH1A1 (0.53) | RHEBKDM4EHPGD | |
| SCHEMBL23148145 | 0.81 | RHEB (0.49) | RHEBIDO1TDO2EIF4A3KDM4E | |
| SCHEMBL23147975 | 0.79 | IDO1 (0.47) | RHEBIDO1TDO2EIF4A3KDM4E | |
| SCHEMBL1144683 | 0.79 | IDO1 (0.55) | RHEBIDO1TDO2EIF4A3KDM4E | |
| SCHEMBL28461413 | 0.78 | GRIN1 (0.64) | RHEBEIF4A3KDM4EHPGDGRIN1 | |
| SCHEMBL8198168 | 0.76 | ALDH1A1 (0.46) | RHEBKDM4EHPGD | |
| SCHEMBL8214927 | 0.75 | DYRK1A (0.39) | KDM4EDYRK1A | |
| SCHEMBL28583335 | 0.75 | ULK1 (0.69) | RHEBIDO1TDO2EIF4A3KDM4E | |
| SCHEMBL7038970 | 0.75 | SRD5A2 (0.46) | RHEBIDO1TDO2 | |
| SCHEMBL30396959 | 0.74 | KDM4E (0.49) | RHEBIDO1TDO2EIF4A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | RHEB 4834/4885IDO1 476/4885TDO2 382/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | RHEB 4834/4885IDO1 476/4885TDO2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.